FI3798222T3 - Lorlatinibin vapaan emäksen kidemuoto - Google Patents
Lorlatinibin vapaan emäksen kidemuoto Download PDFInfo
- Publication number
- FI3798222T3 FI3798222T3 FIEP20202336.2T FI20202336T FI3798222T3 FI 3798222 T3 FI3798222 T3 FI 3798222T3 FI 20202336 T FI20202336 T FI 20202336T FI 3798222 T3 FI3798222 T3 FI 3798222T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- composition according
- free base
- weight
- ppm
- Prior art date
Links
- 239000012458 free base Substances 0.000 title claims 11
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 title claims 11
- 229950001290 lorlatinib Drugs 0.000 title claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 238000001144 powder X-ray diffraction data Methods 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LEHJCMYPLJNJNF-UHFFFAOYSA-N 15-oxa-3,6,7,12-tetrazatricyclo[15.4.0.05,9]henicosa-1,3,5,7,9,11,13,16,18,20-decaene-8-carbonitrile Chemical compound O1C=CN=CC=C2C(C#N)=NN=C2C=NC=C2C=CC=CC2=C1 LEHJCMYPLJNJNF-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199418P | 2015-07-31 | 2015-07-31 | |
| US201662352349P | 2016-06-20 | 2016-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3798222T3 true FI3798222T3 (fi) | 2023-11-28 |
Family
ID=56686850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20202336.2T FI3798222T3 (fi) | 2015-07-31 | 2016-07-27 | Lorlatinibin vapaan emäksen kidemuoto |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10420749B2 (enExample) |
| EP (2) | EP3798222B1 (enExample) |
| JP (1) | JP6218253B2 (enExample) |
| KR (1) | KR102088188B1 (enExample) |
| CN (3) | CN107849060A (enExample) |
| AU (1) | AU2016304420B2 (enExample) |
| BR (1) | BR112017028604A2 (enExample) |
| CA (1) | CA2937257C (enExample) |
| CY (1) | CY1123689T1 (enExample) |
| DK (2) | DK3328867T3 (enExample) |
| ES (2) | ES2842302T3 (enExample) |
| FI (1) | FI3798222T3 (enExample) |
| HK (1) | HK1252845A1 (enExample) |
| HU (2) | HUE052790T2 (enExample) |
| MX (2) | MX382600B (enExample) |
| PL (2) | PL3328867T3 (enExample) |
| PT (2) | PT3328867T (enExample) |
| RU (1) | RU2018101363A (enExample) |
| SG (1) | SG10201913200XA (enExample) |
| SI (2) | SI3328867T1 (enExample) |
| TW (1) | TWI616449B (enExample) |
| WO (1) | WO2017021823A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2998885C (en) | 2015-09-24 | 2020-09-01 | Cyclenium Pharma Inc. | Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| CA3066499A1 (en) * | 2017-06-22 | 2018-12-27 | Cyclenium Pharma Inc. | Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same |
| WO2019073347A1 (en) * | 2017-10-10 | 2019-04-18 | Pfizer Inc. | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN109232607A (zh) * | 2018-09-20 | 2019-01-18 | 沈阳药科大学 | 劳拉替尼的合成方法 |
| MX2021008645A (es) * | 2019-01-17 | 2021-08-19 | Pfizer | Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk). |
| EP3999514A1 (en) * | 2019-07-18 | 2022-05-25 | Pliva Hrvatska D.O.O. | Crystalline lorlatinib : fumaric acid and solid state form thereof |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| CN110530998A (zh) * | 2019-09-16 | 2019-12-03 | 山东省药学科学院 | 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法 |
| EP4041396A1 (en) | 2019-10-10 | 2022-08-17 | Sandoz AG | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011138751A2 (en) | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| EP2822953B9 (en) * | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
| US9637500B2 (en) | 2013-06-28 | 2017-05-02 | Pfizer Inc. | Solid forms of a macrocyclic kinase inhibitor |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| EP3440086B1 (en) | 2016-04-08 | 2020-08-12 | Pfizer Inc. | Crystalline forms of lorlatinib maleate |
| WO2019073347A1 (en) | 2017-10-10 | 2019-04-18 | Pfizer Inc. | CRYSTALLINE BASE FREE HYDRATE SHAPE OF LORLATINIB |
-
2016
- 2016-07-27 MX MX2018001324A patent/MX382600B/es unknown
- 2016-07-27 CN CN201680042321.5A patent/CN107849060A/zh active Pending
- 2016-07-27 HU HUE16751665A patent/HUE052790T2/hu unknown
- 2016-07-27 US US15/743,894 patent/US10420749B2/en active Active
- 2016-07-27 ES ES16751665T patent/ES2842302T3/es active Active
- 2016-07-27 AU AU2016304420A patent/AU2016304420B2/en active Active
- 2016-07-27 DK DK16751665.7T patent/DK3328867T3/da active
- 2016-07-27 PL PL16751665T patent/PL3328867T3/pl unknown
- 2016-07-27 RU RU2018101363A patent/RU2018101363A/ru unknown
- 2016-07-27 EP EP20202336.2A patent/EP3798222B1/en active Active
- 2016-07-27 CA CA2937257A patent/CA2937257C/en active Active
- 2016-07-27 PT PT167516657T patent/PT3328867T/pt unknown
- 2016-07-27 PT PT202023362T patent/PT3798222T/pt unknown
- 2016-07-27 SI SI201631027T patent/SI3328867T1/sl unknown
- 2016-07-27 ES ES20202336T patent/ES2972010T3/es active Active
- 2016-07-27 BR BR112017028604A patent/BR112017028604A2/pt not_active Application Discontinuation
- 2016-07-27 MX MX2021002220A patent/MX395263B/es unknown
- 2016-07-27 KR KR1020187002904A patent/KR102088188B1/ko active Active
- 2016-07-27 HK HK18112176.1A patent/HK1252845A1/zh unknown
- 2016-07-27 HU HUE20202336A patent/HUE065536T2/hu unknown
- 2016-07-27 TW TW105123769A patent/TWI616449B/zh active
- 2016-07-27 PL PL20202336.2T patent/PL3798222T3/pl unknown
- 2016-07-27 JP JP2016146928A patent/JP6218253B2/ja active Active
- 2016-07-27 CN CN202310214099.4A patent/CN116063323A/zh active Pending
- 2016-07-27 SI SI201631780T patent/SI3798222T1/sl unknown
- 2016-07-27 DK DK20202336.2T patent/DK3798222T3/da active
- 2016-07-27 CN CN202310197825.6A patent/CN116063322A/zh active Pending
- 2016-07-27 FI FIEP20202336.2T patent/FI3798222T3/fi active
- 2016-07-27 EP EP16751665.7A patent/EP3328867B9/en active Active
- 2016-07-27 SG SG10201913200XA patent/SG10201913200XA/en unknown
- 2016-07-27 WO PCT/IB2016/054483 patent/WO2017021823A1/en not_active Ceased
-
2019
- 2019-08-08 US US16/535,747 patent/US11020376B2/en active Active
-
2020
- 2020-12-30 CY CY20201101227T patent/CY1123689T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3798222T3 (fi) | Lorlatinibin vapaan emäksen kidemuoto | |
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| MX2015010858A (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| MY169142A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| MX347040B (es) | Inhibidores de tirosina-cinasas. | |
| MX2010003668A (es) | Derivados de purina sustituidas con primidina. | |
| MX2013002259A (es) | Imidazolonilquinolinas [4, 5-c] como inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2015005772A (es) | Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| WO2011121418A9 (en) | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | |
| IN2012DN02577A (enExample) | ||
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| WO2012017239A3 (en) | 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors | |
| NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
| TR201821217T4 (tr) | Tirozin kinaz aktivitesinin inhibisyonu için yeni kaynaşmış pirimidin türevleri. | |
| MX2009008953A (es) | Compuestos como inhibidores de angiogenesis. | |
| MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
| MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| PH12017502007A1 (en) | Crystals of azabicyclic compound | |
| MY199042A (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| MX2014011354A (es) | Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms. | |
| PH12017501690B1 (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
| WO2014016849A3 (en) | Novel triazine compounds |